JDOC JPMorgan Healthcare Leaders ETF

ETF on NASDAQ (US) · Actively managed · Listing

Daily holdings file Nov 17, 2026 Published at am.jpmorgan.com
Book $9.88M 57 positions
Line items 57
In top 10 49%
Largest holding: Eli Lilly and Company ($868K) 8.8%
Portfolio date Nov 17, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Eli Lilly and Company, 613 shares ($868K).

Eli Lilly and Company: 8.8% AbbVie Inc.: 8.5% UnitedHealth Group Incorporated: 5.2% Johnson & Johnson: 4.8% NOVARTIS AG COMMON STOCK: 4.6% Thermo Fisher Scientific Inc: 4.3% ASTRAZENECA PLC COMMON: 4.1% Merck & Company, Inc.: 3.5% Danaher Corporation: 2.8% Intuitive Surgical, Inc.: 2.6% The other 47 positions: 51.0% $9.88M Holdings value
Current positions Top 10 % of book
Eli Lilly and Company LLY $868K 8.8%
AbbVie Inc. ABBV $837K 8.5%
UnitedHealth Group Incorporated UNH $512K 5.2%
Johnson & Johnson JNJ $471K 4.8%
NOVARTIS AG COMMON STOCK NOVN $451K 4.6%
Thermo Fisher Scientific Inc TMO $427K 4.3%
ASTRAZENECA PLC COMMON AZN $406K 4.1%
Merck & Company, Inc. MRK $345K 3.5%
Danaher Corporation DHR $276K 2.8%
Intuitive Surgical, Inc. ISRG $254K 2.6%

Slices are % of holdings value.

Healthcare: 73.8% Unclassified: 26.2% 1 sectors
Sectors % of long value
Healthcare 73.8%
Unclassified 26.2%
Drug Manufacturers - General: 27.6% Biotechnology: 13.7% Medical Devices: 10.0% Healthcare Plans: 8.6% Medical Instruments & Supplies: 4.3% Medical Distribution: 3.8% Health Information Services: 2.0% Other (3): 3.8% Unclassified: 26.2% 10 industries
Industries % of long value
Drug Manufacturers - General 27.6%
Biotechnology 13.7%
Medical Devices 10.0%
Healthcare Plans 8.6%
Medical Instruments & Supplies 4.3%
Medical Distribution 3.8%
Health Information Services 2.0%
Other (3) 3.8%
Unclassified 26.2%

Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (am.jpmorgan.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The Fund seeks to provide long-term capital appreciation.

Principal investment strategies

The Fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies (Healthcare Companies) which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. The Fund will invest in common stocks of Healthcare Companies across all market capitalizations, but expects to invest a majority of its assets in mid- and large- capitalization companies. The Fund will invest globally, including in both developed and emerging market countries, although it expects to invest a majority of its Assets in Healthcare Companies located in the U.S. Prior to June 1, 2026, under normal circumstances, the Fund invests at least 80% of its Assets in the equity securities of Healthcare Companies. The adviser determines that a security is generally appropriate for the Fund if at least 50% of the issuer's assets, revenues, or net income is related to, or derived from, the group of industries in the healthcare sector. "Assets" means net assets, plus the amount of any borrowings for investment purposes. Effective June 1, 2026, under normal circumstances, the Fund will invest at least 80% of its Assets in the equity securities of Healthcare Companies that the adviser considers to be leaders. The adviser determines that a security is generally appropriate for the Fund if at least 50% of the issuer's assets, revenues, or net income is related to, or derived from, the group of industries in the healthcare sector. In addition, leaders are those that the adviser believes are above median compared to Healthcare Companies, based on one or more of the following attributes: revenue growth, free cash flow growth, earnings per share growth, free cash flow margin and operating margin, all of which may be considered on a projected or a historic basis. "Assets" means net assets, plus the amount of any borrowings for investment purposes. 1 The Fund's equity securities may include common stock and depositary receipts. Depositary receipts are financial instruments representing a foreign company's publicly traded securities. A depository receipt trades on a stock exchange in a country different from the company's local market. Derivatives, which are instruments that have a value based on another instrument, exchange rate or index, may be used as substitutes for securities in which the Fund can invest. The Fund may use options, futures and other derivatives for risk management purposes and to provide equity market exposure. For example, the Fund may use exchange-traded futures to gain exposure to particular securities or markets and for the efficient management of cash flows. In addition, the Fund may invest in securities denominated in any currency and may from time to time hedge a portion of its foreign currency exposure using currency forwards. The Fund has a fundamental policy to concentrate its investments in a group of industries in the healthcare sector. This means that the Fund will invest 25% or more of its total assets across a group of industries in the healthcare sector. Investment Process: The Fund seeks to take advantage of the upside potential in the healthcare sector by investing in Healthcare Companies that the adviser believes the market underappreciates. In choosing securities to purchase, the adviser internally evaluates issuers to identify those that, in the adviser's view, are leaders in the healthcare sector. The adviser leverages its proprietary research capabilities to identify these companies, with coverage provided by a team of dedicated healthcare specialists located around the world. Healthcare Companies that the adviser believes are "leaders" include those that have "catalysts" that the adviser believes will lead them to outperform their peers.

Management and Contact

Adviser
J.P. Morgan Investment Management Inc.
Portfolio managers

Dominic Valder (since 2023, Executive Director);

Bartjan van Hulten (since 2024, Managing Director)

Phone
1-844-457-6383

Track Record as of Dec 31, 2025

1 Year Since Inception
Return Before Taxes 14.94% 12.23%
Return After Taxes on Distributions 14.70% 11.11%
Return After Taxes on Distributions and Sale of Fund Shares 9.02% 9.05%
MSCI WORLD HEALTH CARE INDEX (Net Total Return) (Reflects No Deduction for Fees, Expenses, or Taxes, Except Foreign Withholding 14.83% 12.16%
MSCI WORLD INDEX (Net Total Return) (Reflects No Deduction for Fees, Expenses, or Taxes, Except Foreign Withholding Taxes) 21.09% 25.96%

Holdings as of Nov 17, 2026

61 lines, 38 linked, weights sum to 99.96% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
ELI LILLY AND COMPANY LLY Equity 613 0 8.78% $ 867.732K
ABBVIE INC COMMON STOCK ABBV Equity 2,858 0 8.47% $ 836.88K
UNITEDHEALTH GROUP INC UNH Equity 1,313 0 5.18% $ 511.65K
JOHNSON & JOHNSON COMMON JNJ Equity 1,689 0 4.76% $ 470.724K
NOVARTIS AG COMMON STOCK
NOVN Equity 2,840 0 4.56% $ 450.598K
THERMO FISHER SCIENTIFIC TMO Equity 622 0 4.32% $ 427.183K
ASTRAZENECA PLC COMMON
AZN Equity 2,233 0 4.11% $ 406.041K
MERCK & CO INC COMMON MRK Equity 2,407 0 3.49% $ 345.092K
DANAHER CORP COMMON STOCK DHR Equity 1,223 0 2.79% $ 276.117K
INTUITIVE SURGICAL INC ISRG Equity 590 0 2.57% $ 254.013K
NOVO NORDISK A/S COMMON
NOVO-B Equity 6,019 0 2.48% $ 245.092K
CENCORA INC COMMON STOCK COR Equity 663 0 2.35% $ 232.421K
STRYKER CORP COMMON STOCK SYK Equity 671 0 2.16% $ 213.069K
BRISTOL-MYERS SQUIBB CO BMY Equity 3,342 0 2.07% $ 205.032K
REGENERON PHARMACEUTICALS REGN Equity 213 0 2.06% $ 204.003K
IQVIA HOLDINGS INC COMMON IQV Equity 777 0 2.03% $ 200.155K
TAKEDA PHARMACEUTICAL CO
4502 Equity 4,600 0 2.02% $ 199.977K
HUMANA INC COMMON STOCK HUM Equity 441 0 1.98% $ 195.513K
EDWARDS LIFESCIENCES CORP EW Equity 1,827 0 1.95% $ 192.621K
ARGENX SE COMMON STOCK
ARGX Equity 201 +186 1.92% $ 189.557K
ROCHE HOLDING AG COMMON
ROP Equity 377 0 1.84% $ 181.829K
BAYER AG COMMON STOCK EUR
BAYN Equity 2,707 0 1.69% $ 167.063K
BIOGEN INC COMMON STOCK BIIB Equity 663 0 1.68% $ 166.274K
VERTEX PHARMACEUTICALS VRTX Equity 299 0 1.62% $ 159.726K
HCA HEALTHCARE INC COMMON HCA Equity 305 0 1.55% $ 152.863K
GENMAB A/S
GMAB Equity 295 0 1.54% $ 152.412K
CARDINAL HEALTH INC CAH Equity 521 0 1.47% $ 145.489K
TEVA PHARMACEUTICAL
TEVA Equity 3,445 0 1.46% $ 143.987K
CENTENE CORP COMMON STOCK CNC Equity 1,935 0 1.42% $ 140.384K
SANDOZ GROUP AG COMMON
SDZ Equity 1,359 0 1.36% $ 134.164K
ZOETIS INC COMMON STOCK ZTS Equity 1,541 0 1.30% $ 128.643K
FRESENIUS SE & CO KGAA
FRE Equity 1,831 0 1.09% $ 108.171K
ZIMMER BIOMET HOLDINGS ZBH Equity 981 0 1.01% $ 100.15K
CHARLES RIVER CRL Equity 289 0 0.97% $ 95.994K
CASH
Cash 93,373 0 0.94% $ 93.373K
NEUROCRINE BIOSCIENCES NBIX Equity 540 0 0.91% $ 89.597K
ABBOTT LABORATORIES ABT Equity 803 0 0.85% $ 84.082K
REVOLUTION MEDICINES INC RVMD Equity 469 0 0.77% $ 76.302K
DISC MEDICINE INC COMMON IRON Equity 891 0 0.69% $ 68.224K
MEDTRONIC PLC COMMON MDT Equity 622 0 0.64% $ 63.643K
BRIDGEBIO PHARMA INC BBIO Equity 822 0 0.64% $ 63.13K
CONVATEC GROUP PLC COMMON
CTEC Equity 18,179 0 0.60% $ 59.136K
PTC THERAPEUTICS INC PTCT Equity 790 0 0.48% $ 47.684K
DYNE THERAPEUTICS INC DYN Equity 2,968 0 0.48% $ 47.547K
SPYRE THERAPEUTICS INC SYRE Equity 492 0 0.47% $ 46.155K
ALIGN TECHNOLOGY INC ALGN Equity 271 0 0.45% $ 44.298K
LB PHARMACEUTICALS INC LBRX Equity 1,059 0 0.43% $ 42.678K
BOSTON SCIENTIFIC CORP BSX Equity 792 0 0.34% $ 34.08K
JPMORGAN U.S. GOVERNMENT
MGMXX Money market 27,466 0 0.28% $ 27.466K
LEGEND BIOTECH CORP ADR LEGN Equity 1,539 0 0.25% $ 24.793K
APNIMED INC COMMON STOCK APMD Equity 1,276 0 0.23% $ 22.713K
INSMED INC COMMON STOCK INSM Equity 127 0 0.16% $ 15.476K
ARGENX SE
ARGX Equity 15 0 0.14% $ 14.146K
GSK PLC COMMON STOCK GBP
GSK Equity 521 0 0.13% $ 12.822K
ISRAELI SHEKEL
Other 6,479 0 0.02% $ 1,991.99
SWISS FRANC
Cash 1,103 +1,103 0.01% $ 1,313.21
SARTORIUS AG PREFERENCE
SRT3 Equity 1 0 0.00% $ 320.41
DANISH KRONE
Other 0 0 0.00% $ 0.00
JAPANESE YEN
Cash short -3 0 0.00% $ -0.02
BRITISH POUND
Cash 0 0 0.00% $ -0.25
EURO
Cash 0 0 0.00% $ -0.66

Trades Nov 16, 2026 to Nov 17, 2026

Holding Ticker Action Before After Change Value

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up